Obermatt

SCHOTT Pharma AG & Co

GER:1SXP · DE000A3ENQ51
Life Sciences Tools & ServicesMedium

360

62
EV / EBIT75
Price / Owner Earnings32
Owner Earnings Yield77
Dividend Yield1
Price/Sales48
EV / Gross Profit55
Price/Book54
Return on Capital85
Cash Return on Capital75
Return on Equity84
EBIT Margin72
Gross Profitability62
Cash Conversion39
Accruals11
Owner Earnings Margin64
Sales growth19
Profit Growth78
Long-Term EPS Growth34
Owner Earnings Growth75
Reinvestment33
Price momentum13
Debt load63
Refinancing73
Debt Payback45
Liquidity84
Analyst ratings13
Opinion Changes50
Price Target Upside41
Market mood83
Value Creation14/20strong value creator
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

SCHOTT Pharma AG & Co generates returns well above its cost of capital, the foundation of durable shareholder value.

Profile

CountryGermany
IndustryLife Sciences Tools & Services
SizeMedium
TypePublic Company
ExchangeXTRA
Founded2022
Employees855
ISINDE000A3ENQ51
Last UpdateApr 2, 2026
Themes
VaccinesPackaging ServicesPain ManagementBiomedical Engineering

Description

SCHOTT Pharma AG & Co. KGaA (SCHOTT Pharma) develops, manufactures, and sells drug containment solutions and delivery systems for injectable drugs for pharmaceutical, biotechnology, and life science industries worldwide. Business Segments The compa…

Analysis

Middle-of-the-road

SCHOTT Pharma AG & Co. KGaA sits in the middle of our grid: average quality, average price, no obvious signal in either direction. Worth noting: the cash the business generates has lagged behind what the income statement shows.

On valuation, the picture is expensive. The owner-earnings multiple stands at 32.8×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around 13% a year, against analyst forecasts of 7%. The gap between price and consensus is worth watching: demanding expectations.

Growth is tepid; the safety picture is sturdy. The company scores 14/20 on our value-creation score: strong value creator. Analyst sentiment is cautious.

Flags to be aware of: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
41
2026

All-time high

57

Mar 2026

All-time low

41

Jun 2026

Average rank

49

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
48
Price/Earnings
39
Price/Book
54
Dividend Yield
1
Value (overall)
30

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare SCHOTT Pharma AG & Co with its peers
PolyPeptide
SWX:PPGN
37
CountryGuernsey
IndustryLife Sciences Tools & Services
SizeSmall
Full Stock Analysis →
Masterflex
GER:MZX
99
CountryGermany
IndustryMachinery
SizeSmall
Full Stock Analysis →
Barratt Redrow
LSE:BTRW
75
CountryUK
IndustryHousehold Durables
SizeLarge
Full Stock Analysis →
OKYO Pharma
NAQ:OKYO
40
CountryUK
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
NewAmsterdam Pharma Company
NMQ:NAMS
16
CountryNetherlands
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
M&G Credit Income Investment Trust
LSE:MGCI
CountryUK
IndustryCapital Markets
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →